Lilly's Foundayo and Zepbound gain CVS Caremark formulary coverage, expanding access for 90 million members at $25 monthly co-pays.
Eli Lilly’s flagship obesity medications will be included in CVS Caremark formularies, likely boosting sales in the most competitive commercial drug market.
The company
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
CVS Caremark will start covering Eli Lilly's Foundayo and resume covering its Zepbound obesity drugs in the next several months,…
The pharmacy benefits manager also plans to add the weight loss pill Foundayo to its formulary next month.
CVS will add Zepbound coverage on Oct. 1, and start covering Lilly's newly approved Foundayo pill on June 1.
The pharmacy benefit manager dropped Zepbound a year ago in favor of rival Wegovy — now both Lilly and Novo Nordisk drugs will be…
The top pharmacy benefit manager (PBM) in the U.S., CVS Caremark, will
This move marks a pivotal shift for patients seeking access to these highly sought-after treatments
CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans
